Sequoia Vaccines, Inc., founded in 1995, is a clinical-stage pharmaceutical company dedicated to the discovery and development of novel vaccines and anticancer compounds. Their core mission is to prevent bacterial infections, including recurrent urinary tract infections (UTIs), and to treat certain cancers and lung infections associated with cystic fibrosis using small molecules. Sequoia Vaccines focuses on evolving innovative solutions to combat antimicrobial resistance, aiming to improve global health outcomes through prevention and targeted treatments.

Notable affiliated individuals include leading scientists and researchers in the fields of microbiology and oncology. The company has attracted significant investment from venture capital firms specializing in biotech innovations. Key achievements include advancing multiple vaccine candidates into clinical trials and developing a robust pipeline of programs targeting critical health issues. Sequoia Vaccines has made a substantial impact by addressing unmet medical needs and contributing to the global effort against antibiotic-resistant infections and cancer.